Design your plan around a direct front door to care
Rezilient helps keep members within your plan design for high quality care and maximum cost containment.
TRusted by leading health plan partneers
Your customers are facing near-insurmountable barriers to accessing healthcare
The cost of employer sponsored health benefits has quadrupled since the year 2000, and it’s rising every year. And employees often face waits of up to 7 months for routine, in-network primary care visits.
These two factors mean people are skipping preventative care, leading to unnecessary hospitalizations and avoidable chronic conditions.
If a patient has one or more primary care visits per year, their likelihood of receiving preventative health interventions increased by:
Mammogram
75%
Colonoscopy
122%
Vaccinations
127%
Which means they’re less likely to be hospitalized or need intensive treatment.
With Rezilient integrated into your health plan, members get zero-dollar, same-day access to primary, urgent and specialty care, plus hands-on care navigation to keep them within your plan design.
It’s simple: better access to primary care means people stay healthier.
They need fewer visits, less urgent care, and fewer hospitalizations, saving your plan, your customers, and their employees a lot of money.
WHY REZILIENT health?
Ensure your plan reduces costs for employers while delivering high quality care for members
Your health plan is designed to deliver employers value and measurable results, and members exceptional healthcare. So you need a front door that ensures it does exactly that.
With Rezilient, employers pay one transparent monthly fee, members gain immediate, zero-dollar access to primary, urgent, and specialty care, and hands-on care navigation to keep them within your plan design.
We don’t just talk about outcomes. We deliver them.
12%
Average employer healthcare costs savings after first year
33%
Average employee activation rate across 400+ employers
90
Average NPS for CloudClinic and at-home telehealth
Rezilient ranks above the 90th percentile for all key national in-person primary care measures
Asthma Medication Ratio
55-95%
91%
95%
Controlling High Blood Pressure
0-87%
74%
89%
Colorectal Cancer Screening
6-94%
67%
87%
HbA1c Control < 8.0%
0-80%
69%
88%
HbA1c Poor Control > 9.0%
16-100%
20%
4%
Immunizations for Adolescents
0-76%
46%
83%
Acute Hospital Utilization
0-174 PTMY
18 PTMY
15 PTMY
Emergency Department Utilization
19-817 PTMY
107 PTMY
32 PTMY
OUR CORE PRODUCT
Employer profile
Self-insured employers with or without an existing DPC solution who want better control over their healthcare costs.
Payment models
Employers pay a predictable monthly fee, patients pay $0 out-of-pocket for any service provided by Rezilient.
CloudClinic locations
CloudClinics are located in MO, TX, and OK, with more coming. Employers located outside CloudClinic areas are eligible for virtual-only care.
Care delivery
Primary care, urgent care, and specialty care delivered at CloudClinics, via at-home telehealth, and 24/7 messaging. All backed by hands-on care coordination.
“It’s changed our business. Our healthcare costs have been reduced significantly. We're not getting 22% increases in our premiums anymore because our employees are healthy — they're actually going to the doctor."
Stacie Harrell, Human Resources Director at Cosmos
Rezilient customer since 2022
We’re here to help.
Talk to our expert team to find out how Rezilient could change your healthcare game.
Latest Insights
Why improving musculoskeletal health is a strategic priority for employers
Musculoskeletal conditions affect more than half of Americans, impacting both employee wellbeing and company finances.
Introducing Rezilient Multispecialty Care
Our new Multispecialty Care vertical allows us to introduce focused specialty programs to address the most critical healthcare needs of our patient populations.
Danish Nagda included in the St. Louis Business 500
Danish Nagda named as one of the region's top business leaders
Is the GLP-1 compounding boom over?
The FDA has officially declared an end to the supply squeeze on Novo Nordisk's GLP-1 semaglutide, which is also branded as Ozempic and Wegovy.